Peer Review History

Original SubmissionMarch 19, 2025
Decision Letter - Yoshinori Marunaka, Editor

PONE-D-25-14301Prostaglandin E2 dependent migration of Human Brain Endothelial Cells is mediated through Rho-Kinase-IIPLOS ONE

Dear Dr. Khan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 23 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Yoshi

Prof. Yoshinori Marunaka, MD. PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1.  Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf   and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://academic.oup.com/jleukbio/article-abstract/105/4/705/6935763?redirectedFrom=fulltext&login=false

https://d.docksci.com/post-polymerization-crosstalk-between-the-actin-cytoskeleton-and-microtubule-net_5a0eb427d64ab2eca1fa284b.html

https://www.thno.org/v08p6053.htm

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

3. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, and (2) efforts to alleviate suffering.

4. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

5. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This work was supported by grants DSR KFU”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The author(s) received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its supporting information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

7. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: It is well structured and nicely written research work. Similar work has been done before but you have added animal study to it. The work is generally acceptable but you need to make it concise and to the point with results and findings more magnified.

Reviewer #2: In the current manuscript, the authors report that Prostaglandin E2 (PGE2) plays a crucial role in the migration of Human Brain Endothelial Cells through the activation of Rho Kinase II (ROCK-II). The paper is well written and organized. However, following are the concerns:

Major comments

1. In Figure 5a, the pMLC band after the addition of PGE2 appears thinner and weaker than the bands observed under the same conditions in Figures 5b and 5c (+PGE2 lanes). It is unclear why such a discrepancy occurs. Additionally, the authors state that the membrane used to detect pMLC was reprobed to detect total MLC. However, the shapes and widths of the respective bands appear to differ (for example, in Figure 5c). If the same membrane was used for both detections, the band shapes for pMLC and MLC should be identical.

If different membranes were used instead, the authors should clearly indicate this and ideally provide results obtained from the same membrane.

2. In Figure 6, the image showing actin polymerization is not very clear.

In particular, in Figure 6b, the authors state that “NS-siRNA has no effect,” but the development of F-actin is not readily discernible.

If a higher-quality image is available, I would suggest replacing the current one.

3. The authors performed a mouse aortic ring sprouting assay and showed that pretreatment with Y27632 repressed angiogenic sprouting/aorta outgrowth in Figure 7.

However, I was unable to understand how they reached this conclusion.

Would it be possible to quantitatively analyze the results as done in the following paper?

https://doi.org/10.1016/j.mbplus.2020.100025

Minor comments

1. The order of the samples in the PCR results is confusing (in Figure 1). Could this be corrected?

2. I would like to see the units standardized. For example, “0.1 nM” in the figure and “100 pM” in the text (page 10, line 296 and 300), etc.

3. There is no Figure 3c, but the text refers to Fig 3c in page 11 (is it a mistake for Fig 3b?).

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Reviewer’s comments

Reviewer #1:

Comment:

It is well structured and nicely written research work. Similar work has been done before but you have added animal study to it. The work is generally acceptable but you need to make it concise and to the point with results and findings more magnified.

Response:

Thank you for your valuable comments and constructive suggestions on our manuscript. We appreciate your positive feedback. In response, we have revised the manuscript to improve its clarity, conciseness, and overall focus. The edited sections have been clearly highlighted for your convenience. We have also refined the presentation of our results and findings to ensure better clarity and scientific rigor. Furthermore, we have enhanced the quality of several figures to improve readability and facilitate a clearer understanding of the data presented.

Reviewer #2:

In the current manuscript, the authors report that Prostaglandin E2 (PGE2) plays a crucial role in the migration of Human Brain Endothelial Cells through the activation of Rho Kinase II (ROCK-II). The paper is well written and organized. However, following are the concerns:

Comment 1:

In Figure 5a, the pMLC band after the addition of PGE2 appears thinner and weaker than the bands observed under the same conditions in Figures 5b and 5c (+PGE2 lanes). It is unclear why such a discrepancy occurs. Additionally, the author’s state that the membrane used to detect pMLC was reprobed to detect total MLC. However, the shapes and widths of the respective bands appear to differ (for example, in Figure 5c). If the same membrane was used for both detections, the band shapes for pMLC and MLC should be identical. If different membranes were used instead, the authors should clearly indicate this and ideally provide results obtained from the same membrane.2.

Response 1:

We thank the reviewer comments/concern. We have modified Figure 5a accordingly. Separate experiments were conducted for pMLC and total PMC blotting, and each was reprobed with β-Actin antibody independently as a loading control. This clarification has been incorporated into the Materials and Methods section under the subheading Immunoblotting (page 8, lines 236–242), as well as in the figure legend page (page 22, lines 726–731) in the revised manuscript.

Comments 2:

In Figure 6, the image showing actin polymerization is not very clear. In particular, in Figure 6b, the authors state that “NS-siRNA has no effect,” but the development of F-actin is not readily discernible. If a higher-quality image is available, I would suggest replacing the current one.

Response 2:

We thank the reviewer for their valuable observation regarding Figure 6a & 6b. To improve the clarity and visibility of F-actin polymerization, we have updated the figures with higher-magnification images in BOX. Specifically, images were originally acquired at both 20X and 40X magnification. In the revised version, we selected a representative region from the 20X image and magnified it using 40X to enhance resolution and provide a clearer visualization of F-actin structures. This adjustment should allow for better assessment of the statement that "NS-siRNA has no effect." We hope the revised images address the concern effectively. (page 22, line 750-751 and page 23 line 756-757)

Comments 3:

The authors performed a mouse aortic ring sprouting assay and showed that pre-treatment with Y27632 repressed angiogenic sprouting/aorta outgrowth in Figure 7.However, I was unable to understand how they reached this conclusion. Would it be possible to quantitatively analyse the results as done in the following paper? https://doi.org/10.1016/j.mbplus.2020.100025

Response 3:

We thank you the reviewer for the comments. The mouse aortic ring assay is a well-established ex vivo model that recapitulates key processes of angiogenesis, including endothelial cell proliferation, migration, and microvessel sprouting. In our study, we utilized this assay to assess angiogenic activity, employing quantification methods aligned with validated protocols from prior literature. For instance, Nunes et al. (2020) [DOI: 10.1016/j.mbplus.2020.100025] demonstrated that microvessel outgrowth from aortic rings reliably reflects angiogenic potential, allowing for robust quantitative analysis in response to pro- and anti-angiogenic stimuli. Similarly, the PLOS ONE study https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0069552.g002] showed that metrics such as sprout number and cumulative sprout length are sensitive and reliable indicators of angiogenic response. Consistent with these studies, we quantified microvessel sprouting using analogous parameters, including the number and total length of sprouts. This methodological consistency reinforces the validity of our findings and supports the conclusion that the observed sprouting reflects angiogenic induction. Accordingly, we have add and discussed (page 9, line 274-284.Page 14, line 411-419) and Figure 7b legend (page 23, line 767-770) & Two references were added (page 18, line 566-569 & page 20 line 633-636)

Minor comments:

1. The order of the samples in the PCR results is confusing (in Figure 1). Could this be corrected?

Response 1:

Thank you for your valuable comments. We have carefully addressed your feedback and have updated Figure 1 to reflect the correct markings and sequence. Additionally, we have included a box around the relevant area to enhance clarity and ensure the sequence is easily identifiable.

We appreciate your attention to detail and believe these revisions improve the overall presentation of the data.

2. I would like to see the units standardized. For example, “0.1 nM” in the figure and “100 pM” in the text (page 10, line 296 and 300), etc.

Response 2:

Thank you for taking the time to review our work and for providing detailed and insightful comments. We have addressed the unit discrepancy between the Results section and the figure by standardizing all relevant units to "nM." These revisions have been implemented in the updated manuscript, specifically (page 11, lines 317 and 321).

3. There is no Figure 3c, but the text refers to Fig 3c in page 11 (is it a mistake for Fig 3b?).

Response 3:

Thank you for your careful review of our manuscript and for pointing out the error in Figure 3. We appreciate your attention to detail. You are correct that it was incorrectly labelled as 3c instead of 3b. This mistake has been rectified in the revised manuscript, as reflected (page 12, line 343-344).

Attachments
Attachment
Submitted filename: Combined point to point responses.docx
Decision Letter - Yoshinori Marunaka, Editor

PONE-D-25-14301R1Prostaglandin E2 dependent migration of Human Brain Endothelial Cells is mediated through Rho-Kinase-IIPLOS ONE

Dear Dr. Khan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 04 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Yoshi

Prof. Yoshinori Marunaka, MD. PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The higher magnification image in Figure 6b is incorrect.

The high magnification image of “NS-siRNA + PGE2” is identical to that of PGE2 + Y27632 in Figure 6a.

Please check the image carefully again.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  amjed abbawe salih

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 2

Reviewer’s comments

Comments:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article has retracted status in the References list and include a citation and full reference for the retraction notice.

Response:

We sincerely thank the editor for the valuable comments and for highlighting important concerns regarding the references. In response, we have conducted a thorough review of all references cited in the manuscript. We confirm that none of the cited articles have been retracted. All references are recent, relevant, and appropriately aligned with the context, rationale, and scientific content of the manuscript. Additionally, we have ensured consistency and accuracy in formatting using Mendeley Reference Manager, adhering to the PLOS ONE citation style. The revised and verified reference list is provided on pages 17–19, lines 532–620.

Reviewer #2:

Comment:

The higher magnification image in Figure 6b is incorrect. The high magnification image of “NS-siRNA + PGE2” is identical to that of PGE2 + Y27632 in Figure 6a.

Please check the image carefully again.

Response:

We thank the reviewer for their valuable observation regarding Figures 6a and 6b. In response, we have carefully revised and corrected the figures. The updated versions accurately reflect the intended data, and no concerns remain regarding their content.

Attachments
Attachment
Submitted filename: Point to point responses to reviewer comments.docx
Decision Letter - Yoshinori Marunaka, Editor

Prostaglandin E2 dependent migration of Human Brain Endothelial Cells is mediated through Rho-Kinase-II

PONE-D-25-14301R2

Dear Prof. Gausal Azam Khan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yoshi

Prof. Yoshinori Marunaka, MD. PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Yoshinori Marunaka, Editor

PONE-D-25-14301R2

PLOS ONE

Dear Dr. Khan,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Yoshinori Marunaka

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .